Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Scipher Medicine has appointed Sam Asgarian, M.D., MBA, as its new chief medical officer. Dr. Asgarian brings significant experience from Thrive Earlier Detection Corp., a subsidiary of Exact Sciences (EXAS), and from leadership roles at CVS Health (CVS). His expertise aims to enhance Scipher Medicine's mission to match patients with effective therapies, improving outcomes while reducing costs. The company's flagship test, PrismRA, targets rheumatoid arthritis, addressing the substantial issue of ineffective medication prescriptions that costs over $552 billion annually.
Exact Sciences Corp. (Nasdaq: EXAS) reported third-quarter 2021 revenue of $456.4 million, up 12% from $408.4 million in Q3 2020. Screening revenue rose 31% to $280.4 million, while Precision Oncology revenue surged 59% to $145.4 million. However, COVID-19 testing revenue fell 70% to $30.6 million. The company reported a net loss of $166.9 million, improved from $202.5 million a year ago. For 2021, revenue guidance is set between $1,722 million and $1,737 million.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in three upcoming healthcare conferences. These include a fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 10:40 a.m. ET; the Stifel Virtual Healthcare Conference on the same day at 3:20 p.m. ET; and the Evercore ISI HealthCONx Virtual Conference on November 30, 2021, at 11:20 a.m. ET. Investors can access webcasts of these events on the company's investor relations website.
Exact Sciences Corp. (NASDAQ: EXAS) announced data showing that Cologuard (mt-sDNA) significantly reduces colorectal cancer (CRC) incidence and mortality compared to annual fecal immunochemical tests (FIT) in a simulated Medicaid population. The patient navigation system included with Cologuard proved to be cost-effective. Dr. Paul Limburg emphasized the importance of enhancing screening rates, particularly in vulnerable groups. These findings will be presented at the ACG conference, reinforcing Cologuard's position in the market as a valuable tool for early CRC detection.
Exact Sciences Corp. (Nasdaq: EXAS) will release its third quarter 2021 financial results on November 2, 2021, after U.S. market close. A conference call to discuss these results will follow at 5 p.m. ET. The webcast will be accessible via the company's website. This follows the company's focus on developing cancer screening and diagnostic tests, including Cologuard and Oncotype tests. Exact Sciences continues to invest in its product pipeline to enhance support for cancer diagnosis and treatment.
Exact Sciences Corp. (Nasdaq: EXAS) announced participation in upcoming virtual investor conferences, inviting investors to join via webcast. The events include a Fireside Chat at the Wells Fargo Virtual Healthcare Conference on September 9, 2021, at 10:40 a.m. EDT, and another at the Baird 2021 Global Healthcare Conference on September 15, 2021, at 12:15 p.m. EDT. Investors can access the webcasts on Exact Sciences' website. Exact Sciences specializes in cancer screening and diagnostics, focusing on innovative solutions to improve patient care.
Exact Sciences Corp. (Nasdaq: EXAS) received approval from Japan's Ministry of Health, Labor and Welfare for the Oncotype DX Breast Recurrence Score Program. This test aids in chemotherapy treatment decisions for early-stage breast cancer patients. With over 90,000 new cases annually, this approval is crucial for Japanese patients. Exact Sciences aims to obtain coverage under Japan's universal healthcare system and plans to launch the test through its affiliate, Exact Sciences K.K. CEO Kevin Conroy emphasized that this approval marks a significant step in expanding access to advanced cancer tests.
Exact Sciences Corp. (Nasdaq: EXAS) announced the publication of its Oncoguard™ Liver liquid biopsy test performance in Clinical Gastroenterology and Hepatology. The test shows 82% sensitivity for early-stage hepatocellular carcinoma (HCC), with overall sensitivities of 88% and 87% specificity. An estimated 3 million Americans are eligible for HCC testing, but currently, only one in three at-risk patients receive it. Early detection significantly improves five-year survival rates from less than 12% to upwards of 70%.
Exact Sciences Corp. (EXAS) reported Q2 2021 revenue of $434.8 million, a 62% increase from Q2 2020's $268.9 million. Screening revenue rose 101% to $263.9 million, despite a one-time adjustment of $12.1 million. Precision Oncology revenue increased 34% to $137.8 million, while COVID-19 testing revenue decreased 4% to $33.1 million. The company anticipates annual revenue between $1.705 and $1.745 billion, adjusting prior estimates. However, it reported a net loss of $176.9 million ($1.03 per share).
Exact Sciences Corp. (Nasdaq: EXAS) will release its second-quarter 2021 financial results on July 28, 2021, after U.S. markets close. Following the release, a webcast and conference call will be held at 5 p.m. EDT to discuss the financial results and business progress. Interested parties can access the live webcast at Exact Sciences' website. The company is recognized for its cancer screening and diagnostic tests, including Cologuard and Oncotype tests, and continues to invest in its product pipeline to enhance cancer diagnosis and treatment.